Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

New Phase 2 Study In England Features Kinase Inhibitor, AT7519, For Patients With Relapsed Or Refractory Multiple Myeloma

Home/New Phase 2 Study In England Features Kinase Inhibitor, AT7519, For Patients With Relapsed Or Refractory Multiple Myeloma

New Phase 2 Study In England Features Kinase Inhibitor, AT7519, For Patients With Relapsed Or Refractory Multiple Myeloma

The Journal of New England Technology ran this article Friday:

MMRC joins UK biotech in start of multiple myeloma trial
A Phase 2 clinical trial of a treatment for relapsed or refractory multiple myeloma has launched, led by U.K.-based Astex Therapeutics Ltd. and funded by Norwalk, Conn.-based Multiple Myeloma Research Consortium (MMRC). Noopur Raje, of the Massachusetts General Hospital Cancer Center, is named as principal investigator of the trial.

The trial will test the cyclin-dependent kinase (CDK) inhibitor, AT7519, alone and combined with bortezomib (Velcade).

MMRC funded the drug development through its affiliate organization, the Multiple Myeloma Research Foundation (MMRF), and its Biotech Investment Award program. MMRF is the leading private funder of multiple myeloma research worldwide.

Founded in 2004, the MMRC has pushed numerous drug candidates through clinical trials to treat multiple myeloma research, including its January 2009 trial of Zolinza from Merck & Co. and a 2008 study of a four-drug combination of Revlimid, Velcade for injection, Doxil and dexamethasone.

Kinase inhibitor’s are “hot” in multiple myeloma research these days.  The hope is, when combined with proteasome inhibitors, this new combination will shut down myeloma completely.  One can hope, right?
Feel good and keep smiling!  Pat